AIM: To determine if photodynamic therapy (PDT) outcomes are related to lesion size in patients with subfoveal predominantly classic choroidal neovascularisation (CNV) secondary to age related macular degeneration (AMD). METHODS: According to greatest linear dimension (GLD) of the entire lesion determined with fluorescein angiography (FA) patients were divided into two groups. In the first group GLD was <3000 microm and in the second one GLD was 3000-5000 microm. All eyes were treated with standard PDT with the verteporfin protocol. The primary outcome was the proportion of eyes in both groups that did not show significant leakage in FA at the end of follow up. Secondary outcomes were changes in GLD and in best corrected visual acuity (BCVA). RESULTS: 64 patients (mean (SD) age, 76.7 (7.7) years; range 58-95 years) were recruited to participate in the study. All participants in the study completed the follow up time (mean 16.6 months). 24 patients (75%) in the group of smaller lesions (n = 32) compared with 15 patients (46.8%) in the group of larger lesions (n = 32) did not show significant leakage in FA at the end of follow up (p = 0.02). A GLD increase >1000 microm was recorded in nine eyes (28.1%) in the group of smaller lesions and in 16 eyes (50%) in the group of larger lesions (p = 0.07). 22 eyes (68.7%) in the group of smaller lesions compared with 19 eyes (59.3%) in the group of larger lesions lost less than three lines of vision (p = 0.06). Relevant side effects related to verteporfin therapy were not recorded, except for four patients (6.2%) with infusion related back pain. CONCLUSIONS: These results suggest that lesion size at baseline may be a prognosis factor in PDT in patients with subfoveal predominantly classic CNV secondary to AMD. There are no relevant side effects or safety concerns derived from verteporfin therapy.
AIM: To determine if photodynamic therapy (PDT) outcomes are related to lesion size in patients with subfoveal predominantly classic choroidal neovascularisation (CNV) secondary to age related macular degeneration (AMD). METHODS: According to greatest linear dimension (GLD) of the entire lesion determined with fluorescein angiography (FA) patients were divided into two groups. In the first group GLD was <3000 microm and in the second one GLD was 3000-5000 microm. All eyes were treated with standard PDT with the verteporfin protocol. The primary outcome was the proportion of eyes in both groups that did not show significant leakage in FA at the end of follow up. Secondary outcomes were changes in GLD and in best corrected visual acuity (BCVA). RESULTS: 64 patients (mean (SD) age, 76.7 (7.7) years; range 58-95 years) were recruited to participate in the study. All participants in the study completed the follow up time (mean 16.6 months). 24 patients (75%) in the group of smaller lesions (n = 32) compared with 15 patients (46.8%) in the group of larger lesions (n = 32) did not show significant leakage in FA at the end of follow up (p = 0.02). A GLD increase >1000 microm was recorded in nine eyes (28.1%) in the group of smaller lesions and in 16 eyes (50%) in the group of larger lesions (p = 0.07). 22 eyes (68.7%) in the group of smaller lesions compared with 19 eyes (59.3%) in the group of larger lesions lost less than three lines of vision (p = 0.06). Relevant side effects related to verteporfin therapy were not recorded, except for four patients (6.2%) with infusion related back pain. CONCLUSIONS: These results suggest that lesion size at baseline may be a prognosis factor in PDT in patients with subfoveal predominantly classic CNV secondary to AMD. There are no relevant side effects or safety concerns derived from verteporfin therapy.
Authors: Natalie Borodoker; Richard F Spaide; Leandro Maranan; Jane Murray; K Bailey Freund; Jason S Slakter; John A Sorenson; Lawrence A Yannuzzi; David R Guyer; Yale L Fisher Journal: Am J Ophthalmol Date: 2002-02 Impact factor: 5.258
Authors: Neil M Bressler; Jennifer Arnold; Mustapha Benchaboune; Mark S Blumenkranz; Gary E Fish; Evangelos S Gragoudas; Hilel Lewis; Ursula Schmidt-Erfurth; Jason S Slakter; Susan B Bressler; Kelly Manos; Yong Hao; Laurie Hayes; John Koester; Al Reaves; H Andrew Strong Journal: Arch Ophthalmol Date: 2002-11
Authors: Mohammad Azab; Mustapha Benchaboune; Kevin J Blinder; Neil M Bressler; Susan B Bressler; Evangelos S Gragoudas; Gary Edd Fish; Yong Hao; Laurie Haynes; Jennifer I Lim; Ugo Menchini; Joan W Miller; Jordi Mones; Michael J Potter; Al Reaves; Philip J Rosenfeld; Andrew Strong; Xiang Yao Su; Jason S Slakter; Ursula Schmidt-Erfurth; John A Sorenson Journal: Retina Date: 2004-02 Impact factor: 4.256
Authors: Irene Barbazetto; Amy Burdan; Neil M Bressler; Susan B Bressler; Laurie Haynes; Anastasios D Kapetanios; Julius Lukas; Karl Olsen; Michael Potter; Al Reaves; Philip Rosenfeld; Andrew P Schachat; H Andrew Strong; Andrea Wenkstern Journal: Arch Ophthalmol Date: 2003-09
Authors: Francesco Parmeggiani; Carla Enrica Gallenga; Ciro Costagliola; Francesco Semeraro; Mario R Romano; Roberto Dell'Omo; Andrea Russo; Katia De Nadai; Donato Gemmati; Sergio D'Angelo; Elena Bolletta; Francesco Saverio Sorrentino Journal: Sci Rep Date: 2019-02-22 Impact factor: 4.379
Authors: Francesco Parmeggiani; Ciro Costagliola; Francesco Semeraro; Mario R Romano; Michele Rinaldi; Carla Enrica Gallenga; Maria Luisa Serino; Carlo Incorvaia; Sergio D'Angelo; Katia De Nadai; Roberto Dell'Omo; Andrea Russo; Donato Gemmati; Paolo Perri Journal: Int J Mol Sci Date: 2015-08-20 Impact factor: 5.923